Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up​ Enrollment for registrational Phase 3 portion of KYSA-6 trial in MG on track to initiate by year-end 2025 EMERYVILLE, Calif., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that interim data from the Phase 2 portion of the KYSA-6 stud ...